LITESPARK-011, Belzutifan Combinations, and the Enduring Role of Cabozantinib in Sequencing in Advanced RCC

This segment centers on how LITESPARK-011 reshapes the later line treatment landscape while clarifying where cabozantinib continues to fit in modern sequencing. The panel reviews progression free survival improvements observed with belzutifan based combinations compared with cabozantinib, particularly in previously treated patients. Belzutifan, a HIF-2 inhibitor, represents a mechanistically distinct strategy and introduces a new therapeutic dimension beyond VEGF inhibition.

Belzutifan combinations are described as highly active, offering meaningful disease control in patients who require robust tumor reduction. However, increased activity is accompanied by added toxicity. Unlike VEGF targeted TKIs, belzutifan carries unique adverse effects such as anemia and hypoxia. As a result, patient selection becomes central. Individuals with high disease burden, symptomatic progression, or rapidly advancing disease may warrant a more aggressive doublet approach. In contrast, patients with indolent progression, significant prior toxicity, or limited physiologic reserve may benefit from a sequential single agent strategy that prioritizes tolerability.

The discussion then turns to cabozantinib, which remains a foundational therapy despite emerging combinations. Panelists share real world experience with durable responses extending years in selected patients, reinforcing its reliability. Cabozantinib is particularly attractive for patients who may not require combination therapy or who need a manageable and familiar toxicity profile.

Sequencing considerations are emphasized. Prior exposure to certain TKIs may influence later effectiveness and tolerability, making thoughtful line selection important. The overarching message is that innovation expands options but does not eliminate established standards. Instead, clinicians must integrate new data with proven therapies, tailoring treatment intensity to disease biology and patient characteristics.